Sanofi earning slump in 4th quarter

PARIS — The French drug maker Sanofi said its net profit was more than halved in the fourth quarter from a year earlier as mounting restructuring costs and patent losses on key drugs hammered earnings.

Sanofi, the parent of Genzyme Corp., said net profit was $593 million in the October-December quarter. Sales were flat at $11.39 billion. Restructuring costs rose over $133.8 million to $1.1 billion.


The company blamed the loss of US patent protection on two key drugs, Plavix and Avapro, and warned its core earnings per share could fall as much as 5 percent this year. They fell 12.8 percent in 2012.

Associated Press

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of